Skip to content
Review

Efficacy and safety of systemic biological and non-biological therapies for psoriasis. a systematic review and meta-analysis

2026 · International Journal of Medicine in Developing Countries · 0 citations

Abstract

A common chronic skin condition that affects a good number of people worldwide, psoriasis frequently coexists with psoriatic arthritis. The strain this illness places on healthcare systems is substantial. This systematic review and meta-analysis evaluated the efficacy and safety of systemic biological and non-biological therapies for psoriasis. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was followed to extract studies included in this study. Eligible studies included randomized controlled trials (RCTs) on patients with psoriasis or psoriatic arthritis who received biological therapies versus non-biological systemic therapies or controls. The Cochrane risk of bias tool was used to evaluate the quality of RCTs. Data from 16 relevant studies were retrieved and analysed with Resource Manager (RevMan). Sixteen studies were included. Compared with non-biologic therapies, biologics significantly improved PASI 75 (OR ≤ 6.57, 95% CI: 1.39â€"30.96), PASI 90 (OR ≤ 7.68, 95% CI: 1.76â€"33.46), and PASI 100 (OR ≤ 8.00, 95% CI: 2.13â€"29.98). Biologics also showed greater PASI 90 and PASI 100 responses than placebo. Biosimilars had comparable efficacy to reference biologics (PASI 75: OR ≤ 1.58, 95% CI: 0.68â€"3.66). Considerable heterogeneity was observed, while safety outcomes could not be pooled because of inconsistent reporting. Biologic therapies showed greater efficacy than non-biologic treatments for psoriasis, particularly for PASI 90 and PASI 100 responses. However, substantial heterogeneity, methodological limitations, and incomplete safety reporting limit the certainty of these findings. Treatment selection should therefore consider individual patient characteristics, comorbidities, treatment risks, and access to therapy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.